Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. - Wikidata - wikimedia - TriplyDB

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.

http://www.wikidata.org/entity/Q37964938

about

Current therapy of myelodysplastic syndromes Should elderly patients with higher-risk myelodysplastic syndromes undergo allogeneic hematopoietic stem cell transplantation?Emerging biological therapies for the treatment of myelodysplastic syndromes.Impact of copy neutral loss of heterozygosity and total genome aberrations on survival in myelodysplastic syndrome.

P2860

Q34013796-C60C6A9C-33B2-41AA-90AC-6535A4872DB5 Q34013826-737FAB6A-B991-4EE1-96F5-3ED57A3E78F8 Q38834981-438DAB74-3602-47F8-9E71-59F22FB91DF6 Q47305045-949003E6-BBFB-4D9B-AA7E-297141E0B65E

P2860

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.

http://www.wikidata.org/entity/Q37964938

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@en

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@nl

type

label

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@en

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@nl

prefLabel

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@en

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@nl

P1433

Q37964938-F0C7A316-C685-4141-BC43-139D857F4C2E

P1476

Q37964938-41823B1C-42ED-40A3-8ECF-42381F3E645F

P2093

Q37964938-650EC583-BF03-4D5C-BFE2-DF6D749AB363

P2860

Q37964938-008B52DF-B202-4389-874B-23A24A5AD2E4

Q37964938-03B3173C-4651-4360-B589-412D1E4E9B29

Q37964938-0615EE51-3CFF-4B47-8A7F-3E0BD15D7174

Q37964938-07A169EA-D257-4734-921F-DF50651BCC7A

Q37964938-08D2FD5A-C86F-4695-845A-81A7B50E56FB

Q37964938-0B5E03CE-C05A-46EB-A714-BA7B64342F65

Q37964938-1260C3D4-5BB7-45AD-BB46-1139F978D9F4

Q37964938-176E129A-53BF-4C98-A29A-F3191231AA7B

Q37964938-17722324-0DC1-4EB7-81B3-7E0210889F00

Q37964938-17ACBF61-14F2-4189-9DC2-8D2A8BA31C32

P2888

Q37964938-49B53913-526E-4789-B004-150E2C172103

P304

Q37964938-BB8BB552-3D89-4408-B825-35ACCF39CDFC

P31

Q37964938-6AE27DE8-A36D-492C-9110-B9E78C722204

P356

Q37964938-A1521CF5-A4A9-41DD-AA87-1A2A81CB293B

P433

Q37964938-99C37C16-7F38-4D96-B143-C4AA0B345CB0

P478

Q37964938-7F5CB24A-201C-41DF-B275-12F765C69A00

P50

Q37964938-BD3E053B-7254-4E86-96AE-6B56C7710E6C

P577

Q37964938-FA06E596-41D0-48E1-91FF-712EDFF4FE7C

P698

Q37964938-24856E27-3DE1-4011-80D6-92079F8149BB

P356

S00005-011-0152-Z

P1433

Archivum Immunologiae et Therapiae Experimentalis

P1476

Allogeneic hematopoietic cell ...... stic syndrome: current status.

@en

P2093

Matthias Bartenstein

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes.

Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

Hematopoietic stem cell transplantation for MDS.

Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes

Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies.

A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome.

P2888

s00005-011-0152-z

P304

31-41

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00005-011-0152-Z

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

60

http://www.w3.org/2001/XMLSchema#string

P50

Hans Joachim Deeg

P577

2011-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22143157

http://www.w3.org/2001/XMLSchema#string